SCHEMBL1332928

SCHEMBL1332928

OC(CCl)COCCCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1332926 1.00
SCHEMBL17769312 0.89 HSD17B10 (0.40)
SCHEMBL7535158 0.89 CA1 (0.41)
SCHEMBL9447834 0.86 CA1 (0.39)
SCHEMBL9447829 0.86 CA1 (0.39)
SCHEMBL3485216 0.84 HSD17B10 (0.37)
SCHEMBL202567 0.83 CA1 (0.45)
SCHEMBL23559507 0.82
SCHEMBL5021528 0.82
SCHEMBL5832062 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0176991-A1 Composition and method for corrosion inhibition PHILLIPS PETROLEUM COMPANY (US) 1986-04-09 EP claimed
JP-6056811-A None JP disclosed
US-12583853-B2 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases NEWAVE PHARMACEUTICAL INC. (US) 2026-03-24 US disclosed
US-12552784-B2 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases NEWAVE PHARMACEUTICAL INC. (US) 2026-02-17 US disclosed
US-20250114374-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. 2025-04-10 US disclosed
US-12220419-B2 BCL-2 inhibitors NEWAVE PHARMACEUTICAL INC. (US) 2025-02-11 US disclosed
US-20240180924-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. 2024-06-06 US disclosed
US-20240166646-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES NEWAVE PHARMACEUTICAL INC. 2024-05-23 US disclosed
US-11903950-B2 BCL-2 inhibitors NEWAVE PHARMACEUTICAL INC. (US) 2024-02-20 US disclosed
US-20230295183-A1 HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR NEWAVE PHARMACEUTICAL INC. 2023-09-21 US disclosed
JP-H0656811-A PRODUCTION OF GLYCIDYL VINYL ETHER SEIMI CHEM CO LTD 1994-03-01 JP disclosed
US-5093432-A Perfluorination of esters or ethers EXFLUOR RESEARCH CORPORATION (US) 1992-03-03 US disclosed
EP-0441807-A1 LIQUID PHASE FLUORINATION. EXFLUOR RES CORP (US) 1991-08-21 EP disclosed
EP-0436669-A1 PERFLUOROACETAL AND PERFLUOROKETAL COMPOUNDS AND USE THEREOF IN THERMAL SHOCK TESTING MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1991-07-17 EP disclosed
WO-1990003357-A1 PERFLUOROACETAL AND PERFLUOROKETAL COMPOUNDS AND USE THEREOF IN THERMAL SHOCK TESTING MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1990-04-05 WO disclosed
WO-1990003353-A1 LIQUID PHASE FLUORINATION EXFLUOR RESEARCH CORPORATION (US) 1990-04-05 WO disclosed
EP-0137182-B1 PROCESS FOR THE FABRICATION OF POSSIBLY CELLULAR POLYURETHANES BAYER AG (DE) 1986-10-15 EP disclosed
EP-0176991-A1 Composition and method for corrosion inhibition PHILLIPS PETROLEUM COMPANY (US) 1986-04-09 EP disclosed
EP-0137182-A1 Process for the fabrication of possibly cellular polyurethanes BAYER AG (DE) 1985-04-17 EP disclosed
US-4510269-A POLY-DIALKYLAMINOALKYL-ETHER CATALYST BAYER AKTIENGESELLSCHAFT (DE) 1985-04-09 US disclosed